Two NSAIDS, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts

Clinical and Experimental Rheumatology

Volumn 15, Issue 4, 1997, Pages 393-398

  Pelletier, J P ^a,c,d   Mineau, F ^a   Fernandes, J ^a,c,d   Kiansa, K ^a   Ranger, P ^b   Martel Pelletier, J ^a,c,d  

^a NOTRE DAME HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d L C Simard Research Center   (Canada)

Author keywords

IL 6; Naproxen; Nimesulide; Osteoarthritis; PAI 1; uPA

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; METALLOPROTEINASE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

AGED; ARTICLE; CATABOLISM; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; SYNOVIUM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; HUMANS; INTERLEUKIN-6; MALE; NAPROXEN; OSTEOARTHRITIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONAMIDES; SYNOVIAL FLUID; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030879925     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. PELLETIER JP, DIBATTISTA JA, ROUGHLEY P, MCCOLLUM R, MARTEL-PELLETIER J: Cytokines and inflammation in cartilage degradation. In: MOSKOWITZ RW (Ed.): Osteoarthritis, Rheum Dis Clin North Am 1993: 545-68.
2. PELLETIER JP, MARTEL-PELLETIER J, HOWELL DS: Etiopathogenesis of osteoarthritis. In: MCCARTHY DJ, KOOPMAN WJ (Eds.): Arthritis and Allied Conditions: A Textbook of Rheumatology. 13th ed., Philadelphia, Lea & Febiger, 1997; Vol. 2, pg. 1969-84.
3. DEAN DD: Proteinase-mediated cartilage degradation in osteoarthritis. Semin Arthritis Rheum 1991; 20 (S): 2-11.
4. MARTEL-PELLETIER J, MCCOLLUM R, FUJIMOTO N, OBATA K, CLOUTIER J-M, PELLETIER J-P: Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994; 70: 807-15.
5. REBOUL P, PELLETIER J-P, TARDIF G, CLOUTIER J-M, MARTEL-PELLETIER J: The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synovial fibroblasts: A role in osteoarthritis. J Clin Invest 1996; 97: 2011-9.
6. PELLETIER JP, MARTEL-PELLETIER J, ALTMAN RD, GHANDUR-MNAYMNEH L, HOWELL DS, WOESSNER JF JR: Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum 1983; 26: 866-74.
7. PELLETIER JP, MARTEL-PELLETIER J, MALEMUD CJ: Canine osteoarthritis: Effects of endogenous neutral metalloproteases on the proteoglycans. J Orthop Res 1988; 6: 379-88.
8. PELLETIER JP, MARTEL-PELLETIER J, HOWELL DS, GHANDUR-MNAYMNEH L, ENIS J, WOESSNER JF JR: Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983; 26: 63-8.
9. MARTEL-PELLETIER J, CLOUTIER JM, PELLETIER JP: Neutral proteases in human osteoarthritic (OA) synovium. Arthritis Rheum 1986; 29: 1112-21.
10. HE C, WILHELM SM, PENTLAND AP, MARMER BL, GRANT GA, EISEN AZ, GOLDBERG GI. Tissue cooperation in a proteolylic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-5.
11. SERNIOU, FIBBI G, ANICHINI E, ZAMPERINI A et al.: Plasminogen activator and receptor in osteoarthritis. J Rheumatol 1995; 22(S 43): 120-2.
12. MARTEL-PELLETIER J, FAURE M-P, McCOLLUM R, MINEAU F, CLOUTIER J-M, PELLETIER J-P: Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 1991; 18: 1863-71.
13. WERB Z, MAINARDI CL, VATER CA, HARRIS ED JR: Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977; 296: 1017-23.
14. RIJKEN DC: Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillière's Clin Haematol 1995; 8: 291-312.
15. 2 levels in human synovial fibroblasts. Differential stimulation by synovial activator and other cytokines. J Immunol 1989; 143: 971-8.
16. HART DA, REHEMTULLA A: Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp Biochem Physiol 1988; 90B: 691-708.
17. PELLETIER JP, MARTEL-PELLETIER J: Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. Arthritis Rheum 1990; 33: 1466-76.
18. LOTZ M, GUERNE PA: Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity. J Biol Chem 1991; 266: 2017-20.
19. ITO A, ITOH Y, SASAGURI Y, MORIMATSU M, MORI Y: Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992; 35: 1197-201.
20. KISHIMOTO T: The biology of interleukin-6. Blood 1989; 74: 1-10.
21. GUERNE PA, ZURAW BL, VAUGHAN JH, CARSON DA, LOTZ M: Synovium as a source of interleukin-6 in vitro: Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83: 585-92.
22. BROZIK M, ROSZTOCZY I, MERETEY K et al.: Interleukin-6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production. J Rheumatol 1993; 20: 1253-5.
23. ALTMAN R, ASCH E, BLOCH D, et al.: Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum 1986; 29: 1039-49.
24. SADOUK M, PELLETIER J-P, TARDIF G, KIANSA K, CLOUTIER J-M, MARTEL-PELLETIER J: Human synovial fibroblasts coexpress IL-1 receptor type I and type II mRNA. The increased level of the IL-1 receptor in osteoarthritic cells is related to an increased level of the type I receptor. Lab Invest 1995; 73: 347-55.
25. FIBBI G, SERNI U, PUCCI M, CALDINI R, MAGNELLI L, DEL ROSSO M: Plasminogen activators and tiaprofenic acid in inflammation. A preliminary study. Drugs 1988; 35(S): 9-14.
26. PELLETIER J-P, MCCOLLUM, CLOUTIER J-M, MARTEL-PELLETIER J: Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium. Br J Rheumatol 1992; 31 (S1): 19-26.
27. 2 and cAMP. Arthritis Rheum 1986; 29: 1078-84.
28. HAMILTON JA, LEIZER T, LINGELBACH SR: The stimulation of human fibroblast plasminogen activator activity. Involvement of cyclic AMP and cyclooxygenase products. Biochem Biophys Acta 1986; 886: 195-202.
29. SIPE JD, BARTLE LM, LOOSE LD: Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with the clinical acute phase response. J Immunol 1992; 148: 480-4.
30. OUNISSI-BENKALHA H, PELLETIER J-P, TARDIF G et al.: In vitro effects of 2 antirheumatic drugs on the synthesis and expression of proinflammatory cytokines in synovial membranes from patients with rheumatoid arthritis. J Rheumatol 1996; 23: 16-23.
31. ANDERSON GD, HAUSER SD, McGARITY KL, BREMER ME, ISAKSON PC, GREGORY SA: Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin-6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-9.
32. FAMAEY JP: In vitro and in vivo pharmacological evidences of selective cyclo-oxygenase-2 inhibition by nimesulide: An overview. Inflamm Res (in press).
33. GROSSMAN CJ, WISEMAN J, LUCAS FS, TREVETHICK MA, BIRCH PJ: Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and monomuclear cells by NSAIDs and COX2 inhibitors. Inflamm Res 1995; 44: 253-7.
34. PELLETIER J-P, MARTEL-PELLETIER J: Effects of Nimesulide and Naproxen on the degradation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs 1993; 46 (S1): 34-9.